$MDNAF $MDNA (.to) #MDNA11 #IL2 valuation ranges based on the data from the abstract.

$MDNAF $MDNA.to abstract at #ESMO-IO - important to note it's not the final poster as it's only a place-holder data cutoff 09/04 More updated data with most likely mid November will be presented next week 12/10 at the conference! The 2 slides are from AACR25 data cutoff

Yes, anything above 15% in mono and 25% in combo would be very good. But it also depends on -> durability So far durability has been very good also, but.. just a few patients. Durability would be a BIG win. Even if ORR is a (little) lower than in phase 1 . $MDNAF $MDNA (.to)

#MDNA11 ORR predictions ESMO mono vs combo $MDNAF $MDNA (.to) model 1

Some interesting points in this presentation—worth a listen. Good to hear the Takeda deal brought more attention to the IL-2 space, especially to Medicenna’s IL-2 programs. There aren’t many options with this level of quality.

💡Tomorrow: Don’t miss @Medicenna1 live investor webinar Join @Medicenna1 Therapeutics (TSX: $MDNA | OTCQX: $MDNAF) CEO Fahar Merchant as he reviews clinical progress and upcoming catalysts across the company’s #immunotherapy pipeline. 🔗 RSVP here >>

$MDNAF $MDNA (.to) Q2 financial results https://t.co/0vAZmT3Nbe

$MDNAF $MDNA (.to)

#MDNA11 value now, december and next year $MDNAF $MDNA (.to)

#MDNA113 value estimates based on other deals in the PD1-VEGF and PD1-IL2 space $MDNA (.to) $MDNAF

$MDNAF

And even better news, just to clarify, $MDNAF $MDNA.to isn’t funding the trial. It’s being sponsored by the non-profit Melanoma Foundation (Fondazione Melanoma Onlus) at the National Cancer Institute ‘G. Pascale Foundation’. Medicenna will provide the study drugs under a

Now, $MDNAF $MDNA.to will have a new combo, with $BMY's nivolumab!!! MDNA11 will be evaluated in combination with the checkpoint inhibitors nivolumab (anti-PD1) alone or with ipilimumab (anti-CTLA4), with Major Pathologic Response (MPR) as a primary endpoint, which is

This is really interesting step for $MDNAF "Neoadjuvant Combination Trial" $MDNA.to Medicenna and Fondazione Melanoma Onlus Collaborate to Advance MDNA11 Before First-Line Therapy in a Randomized Neoadjuvant Combination Trial, “NEO-CYT”, in High-Risk, Surgically Resectable

$MDNAF $MDNA (.to) 1.03 - up 35% Takeda #IL2 deal seems to make investors understand the potentional of MDNA11 and MDNA113 chart update:

$MDNA.TO $MDNAF Medicenna's updated MDNA11 clinical data from the Phase 1/2 ABILITY-1 Study will be presented at the @myESMO Immuno-Oncology Congress 2025 (Dec 10–12, London 🇬🇧). Presented by Dr. André Mansinho, highlighting MDNA11 alone & with pembrolizumab. #MDNA11

$MDNAF $MDNA.to will present MDNA11 Clinical Data from the ABILITY-1 Study at the European Society for Medical Oncology #ESMO Immuno-Oncology ( #ESMO-IO) Congress 2025 December 10, 2025

The #IL2 space is gaining momentum! $MDNAF's Best-in-Class IL-2 drug shows strong data as a mono and in combo with #Keytruda. Next-gen MDNA113 outperforms IBI363, targeting IL-13Ra2 with a unique IL-13 binding epitope. $TAK is paying $1.2B upfront for 2 candidates!

$MDNAF $MDNA (.to) Youtube replay Emerging Growth Conference 👇 https://t.co/wG8EBjQprJ

$MDNAF $MDNA.to Addressable market in Checkpoint-Resistance #Melanoma cancer